Novartis AG is looking to put virtual clinical trials firmly at the heart of its strategy of digitizing the R&D engine having expanded its alliance with Science 37 to launch up to 10 new studies over the next three years that could be carried out at the patient's home rather than a large hospital.
"We are on an ambitious journey to completely change the clinical development paradigm," Novartis' head of digital development Jake LaPorte told Scrip in an interview, noting that "the current trajectory...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?